We are delighted to announce that ProGenis Pharmaceuticals has been named a finalist in the 2025 WA Innovators of the Year Awards under the Rio Tinto Emerging Innovation category.
This recognition shines a spotlight on PGP-011, our breakthrough RNA therapeutic designed to tackle insulin resistance, the root cause of type 2 diabetes. It reflects years of cutting-edge research, the dedication of our incredible team, and the power of collaboration with partnering organisations committed to transforming innovative diabetes care both locally and globally.
The 2025 WA Innovators of the Year Awards reached a new milestone with a record-breaking 91 applications, showcasing the remarkable depth of talent within Western Australia’s innovation ecosystem. We are proud that ProGenis is among the six finalists in the prestigious Rio Tinto Emerging Innovation category, and honoured to stand alongside other visionary organisations shaping the future of our state.
This recognition represents an exciting opportunity to expand the reach and maximise the impact of PGP-011 in advancing better therapeutic options and management strategies for people living with type 2 diabetes.
We extend our sincere gratitude to the Department of Energy and Economic Diversification, Rio Tinto, and Biodesign Australia, and we congratulate all applicants and finalists for championing innovation across Western Australia and supporting local initiatives with global potential.
For more details: https://lnkd.in/enRNQUQH